On October 13, 2023, a delegation led by Zeng Chunlai, President of Lishui Intellectuals Association and Director of Lishui People's Hospital, conducted an inspection visit to Benefit Pharmaceutical. The delegation included He Qiaoli, Executive President of the Association and Deputy Director of the Legislative Affairs Committee of Lishui Municipal People's Congress; Zhou Minya, Vice President of the Association and Director of Rehabilitation Department at Lishui Second People's Hospital; Zheng Haiya, Deputy Director of the Party-Government Comprehensive Office of Lishui People's Hospital; Yu Menglong, Member of Lishui Overseas-educated Scholars Association and Technical Director of FLS Chemical Engineering (Suichang) Co., Ltd.; and Chen Xueqin, Deputy Director of the Party Non-affiliates and Intellectuals Work Division of Lishui United Front Work Department. The purpose was to investigate Benefit's industrial layout and development plans while attentively reviewing the company's current progress. Accompanying officials included Wei Yesheng, Deputy Director of Economic Promotion Department; Wu Xiongpeng, Deputy Director of Enterprise Service Department at Fuling Industrial Platform Operation Company; and Xu Jianfeng, Staff Member of Party-Mass Work Department. Benefit was represented by Executive Director Wu Liwei, Administrative Director Hu Lizhen, Deputy Project Director Chen Xia, and Chairman's Secretary Che Xin.

Administrative Director Hu Lizhen provided a comprehensive overview of the company's four operational sectors—industrial production, commercial operations, agricultural cultivation, and traditional Chinese medicine healthcare—along with future development strategies.

President Zeng Chunlai and the delegation conducted an on-site inspection of the finished product warehouse for traditional Chinese medicine formula granules. They examined the development prospects and progress of these granules in detail. Executive Director Wu Liwei engaged in technical discussions with the delegation regarding production processes, product convenience, quality assurance, efficacy validation, and clinical outcomes of single-herb formula granules.

During the symposium, President Zeng emphasized that Lishui is vigorously developing the traditional Chinese medicine (TCM) health industry, with municipal authorities showing strong commitment to local TCM enterprises. He stated that this inspection aimed to identify operational challenges, resolve bottlenecks, and foster enhanced collaboration between medical institutions and enterprises. Executive Director Wu Liwei expressed gratitude for the government's consistent support and highlighted TCM's pivotal role in Lishui's "5+5" modern ecological industrial cluster system. She noted that the TCM health industry intersects with multiple strategic sectors: health pharmaceuticals under ecological industries, and quality agriculture, tourism, and forestry under pillar industries. Benefit, she explained, is committed to leveraging secondary industry to drive primary and tertiary sectors while optimizing its industrial chain. Discussions also covered talent recruitment policies, industry-academia collaboration, institutional-enterprise partnership platforms, and TCM services for overseas Chinese communities. President Zeng acknowledged Benefit's developmental achievements and assured that all recommendations would be systematically documented to refine government policies, enhance enterprise productivity, and collectively advance the high-quality development of Lishui's TCM industry.

The delegation's guidance on biomedicine industry development reflects the municipal government's substantive support for enterprises. This initiative not only addresses corporate concerns and bridges resource gaps for public welfare but also demonstrates governmental prioritization of biomedicine advancement and TCM quality enhancement. As a practitioner of modernized TCM, Benefit Pharmaceutical remains committed to active participation and responsibility-sharing. The company is dedicated to contributing distinctive Chinese elements to global health, fulfilling diversified public health demands through superior TCM products, and collectively establishing the TCM industry as a uniquely competitive sector in China.